Drug Eluting Stent News and Research RSS Feed - Drug Eluting Stent News and Research

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.
JACC publishes pivotal data on Tryton’s dedicated coronary bifurcation stent, results submitted to FDA

JACC publishes pivotal data on Tryton’s dedicated coronary bifurcation stent, results submitted to FDA

Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that results from the Tryton Confirmatory Study of the company’s Side Branch Stent have been published in JACC Cardiovascular Interventions. [More]
PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016. [More]
Medinol announces completion of enrollment in BIONICS trial to evaluate effectiveness of eDES

Medinol announces completion of enrollment in BIONICS trial to evaluate effectiveness of eDES

Medinol, a developer of Interventional Cardiology devices, announced today the completion of enrollment in its BIONICS trial, a global, prospective, randomized, multicenter, clinical trial designed to evaluate the safety and effectiveness of a new Coronary Stent System, the first ever elastomeric Drug Eluting Stent or eDES. [More]
Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent. [More]
Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

For the first time, ESC Guidelines published today give the highest degree of recommendation for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS). [More]
ESC Congress to highlight results from global trials in six press conferences

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research. [More]
Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications. [More]

Biosensors’ Q1 FY16 revenue reduces US$67.0M compared to US$80.2M in Q1 FY15

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2015 ("Q1 FY16"). [More]
Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death. [More]
Cardiac catheterization performed through wrist can reduce bleeding, lower mortality

Cardiac catheterization performed through wrist can reduce bleeding, lower mortality

The groin is the usual access point for investigating or treating the heart with a catheter, but using the wrist as access point reduces bleeding and lowers mortality. These findings are from an international study with major involvement from the University of Bern published today in the Lancet. [More]
Extended dual antiplatelet therapy after DES implantation increases mortality

Extended dual antiplatelet therapy after DES implantation increases mortality

Data from a meta-analysis published today in The Lancet found that extended duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with significantly higher rates of mortality compared to shorter DAPT. [More]
Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were opened with balloon angioplasty and stents in a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Cook Medical receives CE Mark for new thumbwheel deployment system for Zilver PTX drug-eluting peripheral stent

Cook Medical receives CE Mark for new thumbwheel deployment system for Zilver PTX drug-eluting peripheral stent

CE Mark has been awarded to the new rotating thumbwheel deployment system for Cook Medical’s Zilver PTX drug-eluting peripheral stent. The new system, which is now available for purchase in the UK, Ireland, Germany, Spain and Italy, provides simple deployment for the world’s first and only approved drug-eluting stent for the superficial femoral artery (SFA). [More]
Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®. [More]
Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color. [More]
Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. [More]

Drug-eluting peripheral stent from Cook Medical selected as a top 10 game-changing health technology for 2014

As announced at the 2014 Canadian Agency for Drugs and Technologies in Health (CADTH) symposium, the Canadian Network for Environmental Scanning in Health (CNESH) has selected Cook Medical’s Zilver® PTX® drug-eluting peripheral stent as a top 10 game-changing health technology for 2014. The CNESH top 10 list is designed to encourage the adoption and use of effective, safe health technologies in Canada. [More]

Zilver® PTX® drug-eluting stent from Cook Medical receives positive one-year follow-up results

One-year follow-up data from 907 Japanese patients who received the Zilver® PTX® drug-eluting stent showed positive results in keeping open the superficial femoral artery (SFA). The postmarket surveillance (PMS) study, designed to evaluate the stent’s performance in real-world patient use, was presented at the 2014 Euro PCR meeting. [More]

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. [More]
BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration (FDA) has approved a significant expansion of its ongoing ProMRI® trial. [More]
Advertisement
Advertisement